Results 171 to 180 of about 295,380 (280)

InflaMix Predicts Severe CRS, ICU Admission, and Progression‐Free Survival After CAR‐T Therapy in LBCL

European Journal of Haematology, Volume 117, Issue 6, Page 1630-1636, December 2026.
ABSTRACT Objectives Baseline systemic inflammation has emerged as a determinant of outcome after CD19‐directed CAR‐T therapy. We evaluated the prognostic performance of the recently developed INFLAmmation MIXture Model (InflaMix) in an independent bicentric cohort of patients with large B‐cell lymphoma (LBCL) receiving commercial CAR‐T cells, focusing ...
Eugenio Galli, Daniele Mannina, Alessandro Corrente, Chiara De Philippis, Ilaria Pansini, Marcello Viscovo, Stefan Hohaus, Patrizia Chiusolo, Federica Sorà, Stefania Bramanti, Simona Sica   +10 more
wiley   +1 more source

FDA Approval Summary: Epcoritamab with Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma. [PDF]

Clin Cancer Res
Ershler R, Zhou X, Peh KH, Wei H, Chatterjee S, Jiang X, Liu J, Okusanya OO, Shen YL, Kormanik N, Carioti T, de Claro RA, Kanapuru B, Gormley NJ, Kasamon YL.   +14 more
europepmc   +1 more source

Targeting B‐Cell‐Activating Factor and Its Receptor in Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia

American Journal of Hematology, Volume 101, Issue 11, Page 2836-2852, November 2026.
ABSTRACT Current treatments for immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA), rare autoimmune diseases in which autoreactive B cells play a major role, can lead to high response rates; however, for many patients these responses are not durable or maintained after treatment discontinuation.
Matthieu Mahévas, Nichola Cooper, Vickie McDonald, Karina Yazdanbakhsh, Wilma Barcellini   +4 more
wiley   +1 more source

Rare Leukemic Phase of Follicular Lymphoma With a High-Risk Follicular Lymphoma International Prognostic Index (FLIPI) Score Treated With Bendamustine-Rituximab. [PDF]

Cureus
Bansal N, Thomas S, Shanmugam SG.
europepmc   +1 more source

Follicular lymphoma of the duodenum [PDF]

Endoscopy, 2007
P, Born, M, Vieth, M, Stolte
openaire   +2 more sources

Shortened Obinutuzumab Infusion Is Safe and Reduces Chair Time in Frontline Treatment of Chronic Lymphocytic Leukemia: A Real‐World Study

Cancer Medicine, Volume 15, Issue 11, November 2026.
In treatment‐naïve CLL, a shortened obinutuzumab infusion was as safe as standard infusion, did not increase infusion‐related reactions, and significantly reduced chair time, improving outpatient unit efficiency. ABSTRACT Background Obinutuzumab‐based regimens are established frontline treatments for chronic lymphocytic leukemia (CLL), but infusion ...
Dominika Écsiová, Eva Vejražková, Pavel Vodárek, Petra Rozsívalová, Lukáš Smolej, Pavel Žák, Martin Šimkovič   +6 more
wiley   +1 more source

Clinical features of primary intestinal follicular lymphoma: A single-center retrospective study. [PDF]

J Int Med Res
Ying CL, Zhao TQ, Pu QX, Huang HC, Liu W.   +4 more
europepmc   +1 more source

Age, Comorbidity Burden and Treatment Outcomes in Mature B‐Cell Lymphoproliferative Disorders: A Real‐World Study

Cancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Introduction Treatment decisions in older patients with mature B‐cell lymphoproliferative disorders (MBLD) are frequently guided by chronological age and comorbidity burden, although their ability to predict clinically relevant outcomes remains uncertain.
Kevin Nasrinfar, Harrison Wildhaber, Rudolf Rohr, Gaëlle Rhyner Agocs, Urban Novak, Alessandra Curioni‐Fontecedro, Vérène Dougoud‐Chauvin   +6 more
wiley   +1 more source

Chimeric antigen receptor T‐cell therapy as a cure for large B‐cell lymphoma

HemaSphere, Volume 10, Issue 11, November 2026.
Abstract Large B‐cell lymphoma (LBCL) is cured in most patients with first‐line chemoimmunotherapy; however, 30%–40% of patients will have relapsed or refractory (R/R) disease. Of these patients, those with refractory or early relapsed LBCL may receive chimeric antigen receptor (CAR) T‐cell therapy as their second‐line treatment if they are eligible ...
Danielle S. Wallace, Yashashree Gupta, Carla Casulo, Wendy Osborne   +3 more
wiley   +1 more source

Management of advanced mycosis fungoides and Sézary Syndrome: International Recommendations for systemic treatments and allogeneic hematopoietic cell transplantation from the European Hematology Association, the EORTC Cutaneous Lymphoma Tumours Group, the International Society for Cutaneous Lymphoma, and the Lymphoma Working Party of the EBMT

HemaSphere, Volume 10, Issue 11, November 2026.
Abstract Advanced mycosis fungoides (MF) and Sézary syndrome (SS) are the most aggressive forms of cutaneous T‐cell lymphoma and remain associated with a poor prognosis and heterogeneous therapeutic approaches. Recent advances, including targeted therapies and improved transplant strategies, have substantially expanded treatment options, highlighting ...
Francesco Onida, Pietro Quaglino, Julia Scarisbrick, Anna Sureda, Emmilia Hodak, Evangelia Papadavid, Silvia Alberti‐Violetti, Martine Bagot, Lorenzo Cerroni, Amrita Goyal‐O'Leary, Rudolf Stadler, Rein Willemze, Jasmine Zain, Marco Ardigò, Emilio Berti, Adèle de Masson, Rafael F. Duarte, Francine Foss, Eva González‐Barca, Joan Guitart, Pablo Ortiz‐Romero, Alessandro Pileri, Pierluigi Porcu, Henry M. Prince, Sima Rozati, Serena Rupoli, Maarten H. Vermeer, Sean Whittaker, Nicola Pimpinelli, Pier Luigi Zinzani   +29 more
wiley   +1 more source